Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

It wasn’t all that long ago that Johnson & Johnson was touting head-to-head results for its psoriasis drug Tremfya against Novartis’ blockbuster Cosentyx. But now, a different rival has topped Tremfya in a showdown of its own.